1 / 1

FRAGILE X SYNDROME NEWSLETTER | FXS Newsletter

Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward.<br><br>Visit to gain access to our Newsletter: https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome<br>

sthakur
Download Presentation

FRAGILE X SYNDROME NEWSLETTER | FXS Newsletter

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FRAGILE X SYNDROME NEWSLETTER Fragile X Syndrome, a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people suffering from it, is a result of mutation associated with the gene known as FMR1. As per DelveInsight assessments, the market size of Fragile X Syndrome (FXS) in the 7MM was found to be USD 33.51 Million in 2017, for the study period, 2017–2028. Top companies involved fuelling the FXS Market are: Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others. Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward. Visit to gain access to our Newsletter: https://www.delveinsight.com/whitepaper- newsletter/fragile-x-syndrome

More Related